Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03896711
Other study ID # IRB00197899
Secondary ID R01AG058586
Status Recruiting
Phase N/A
First received
Last updated
Start date March 1, 2022
Est. completion date September 29, 2024

Study information

Verified date June 2023
Source Johns Hopkins University
Contact Quincy Samus, PhD
Phone 4105506493
Email qmiles@jhmi.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a single blind, intention-to-treat, randomized controlled trial design to evaluate the feasibility and efficacy of a 12-week, evidence-based, individualized MEMORI Corps program delivered by trained older volunteers (n=80) to community-living PWD/CG dyads (n=240). Eligible PWD/CG dyads will be randomized to receive 12-weeks intervention group (n=120), or 12-week augmented waitlist control group (n=120) followed by 12-weeks of intervention. Eligible volunteers will be randomized to 12 months of MEMORI Corps active duty (n=40) where the participants will be matched to three families over the course of a year, or a 12-month augmented waitlist control group (n=40) followed by opportunity to serve 12 months active duty in MEMORI Corps. Program goals are to address unmet respite care needs for family caregivers, provide persons with dementia meaningful evidence-based activity programming, as well as provide health benefits, meaningful productive engagement, and peer support opportunities for senior volunteers.


Description:

In partnership with the Alzheimer's Association, the investigators propose to evaluate in a NIH Stage III (Real World Efficacy) randomized trial, Making Engagement Meaningful through Organized Routine Interaction (MEMORI) Corps, a novel 12-week activity-based companion care model, to mobilize and equip a critical mass of senior volunteers to deliver individualized, evidence-based activity programming to PWD living at home and offer family CGs needed respite. Synthesizing and adapting prior evidence-based work from the Tailored Activities Program® (a proven activity-based intervention to address functional decline and behavioral symptoms in persons with dementia), Experience Corps® (an inter-generational civic engagement program that engages senior volunteers to work in elementary schools to improve academic outcomes for children and improve health outcomes for the volunteers), and MIND at Home® (a home-based dementia care coordination program delivered by non-clinical care coordinators supported by a clinical team), MEMORI Corps takes a social model of health approach to simultaneously address unmet respite care needs of family CGs, provide PWD structured meaningful activities and social engagement, and provide meaningful engagement and peer support opportunities for senior volunteers-creating potential for a "win-win-win" scenario. This single blind, two-arm, randomized controlled trial will evaluate the feasibility and efficacy of a 12-week, evidence-based, individualized MEMORI Corps program delivered by trained senior volunteers (n=80) to community-living PWD and participant's family caregivers (n=240 dyads). Core intervention components include: (1) detailed initial home-based assessment of interests and preserved abilities of PWD; (2) individualized activity program plans based on interests and abilities; (3) training of volunteers in communication and simplification strategies and use of activity program plans; (4) delivery of activity plans by volunteers to PWD over 12 weeks (8 hours/week) in participant's homes; (5) family CG education on activity plans and ways to utilize respite opportunities; and (6) support of volunteers from a skilled multidisciplinary clinical team. PWD/CG outcomes will be assessed at baseline, 6-, and 12-weeks. Volunteer outcomes will be assessed at baseline, 6- and 12-months (volunteer participation lasts 12 months). Specific aims are to evaluate the: Aim 1: Efficacy of the MEMORI Corps intervention on community-living PWD quality of life and neuropsychiatric symptoms at 6- and 12-weeks (primary endpoint) versus augmented wait-list control. Aim 2: Efficacy of MEMORI Corps intervention on CG subjective and objective burden and depressive symptoms at 6- and 12-weeks (primary endpoint) versus augmented wait-list control. Aim 3: Efficacy of MEMORI Corps intervention on volunteer physical function, cognition, and social and psychological engagement at 6-months and 12-months (primary endpoint) versus augmented wait-list control. Aim 4: Acceptability and feasibility of implementing the MEMORI Corps program from various stakeholder perspectives (PWD, informal CGs, senior volunteers, volunteer coordinators/supervisors).


Recruitment information / eligibility

Status Recruiting
Enrollment 560
Est. completion date September 29, 2024
Est. primary completion date September 29, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 115 Years
Eligibility Inclusion Criteria: Persons with dementia and informal caregiver (PWD/CG) must both meet eligibility criteria. These criteria are designed to reduce PWD/CG attrition and ensure safety of PWD, CG, and volunteers. PWD are eligible if: - English speaking - Have an established physician clinical diagnosis of dementia (any stage) and confirmed with the Clinical Dementia Rating Scale of >0.5 - Are able to participate in >2 basic Activities of Daily Living - Have not received formal (e.g. in-home companion care, or adult day center) respite care services in the past 4 weeks - Living at home in Baltimore City or Baltimore County. CGs are eligible if: - English speaking - 18 years of age or older (male or female) - Are deemed to be a reliable informal caregiver (not paid for their care-giving) - Are co-residing with the PWD - Are relied on by the PWD for assistance in activities of daily living (instrumental or basic). Volunteers are eligible if: - English-speaking - 55 years or older - Ability to read - Ability to pass a criminal background check, drug and physical and mental health screening - Have reliable transportation and able to travel within 20 miles of home - A Mini-Mental State Examination score of 24 or above - Ability to complete the Trail Making Test within specified time limits - Ability to commit to 12 months of service (10 hours per week excluding travel time) - Are reliable during intake and on-boarding process. Exclusion Criteria: PWD are excluded - If deemed to be in a crisis/unsafe situation at baseline - Planned transition from home in less than 6 months - At end-stage disease (e.g. bed-bound, non-communicative, or hospice) - Are incontinent of urine or bowels - Are currently enrolled in a dementia related clinical trial - Deemed to have severe behavioral symptoms placing self or others at harm. CGs are excluded if: - Do not plan to be co-residing with the PWD in the next 6 months - Are currently involved in a behavioral/educational clinical trial. Volunteers are excluded: - Are planning on moving from the area in the next 12 months - Unable to provide informed consent.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
MEMORI Corps program
Activity-based companion care program. Delivered by trained senior volunteers, supported by a clinical team, over a 12-week intervention period (8 hours per week, 2 or 3 days per week) for each person with dementia/family caregiver dyad. Primary roles of the volunteers are to provide in-home supervision, peer-to-peer companionship, and a evidence-based individualized activity program that focuses on meaningful, engaging and enjoyable activities that match PWD abilities and interests.
Other:
Augmented Waitlist Control
Persons with dementia/caregivers will continue any services and supports being used, will receive a free copy of "A Caregiver's Guide to Dementia: Using Activities and Other Strategies to Prevent, Reduce and Manage Behavioral Symptom"103), written educational materials on management of CG stress/well-being, and bi-weekly check-in calls to answer any questions about the materials. Volunteers randomized to waitlist control will continue with usual activities (volunteer or other), and will receive additional written educational materials on cognitive health (NIA) and exercise and Physical Activity (Go4Life), referrals to the Baltimore City Commission on Aging and Retirement Education for volunteering opportunities, and bi-monthly check-in calls to answer questions and maintain engagement. Waitlist dyads will be followed at specified intervals by the research team and then offered an opportunity for participation in the intervention arm.

Locations

Country Name City State
United States Johns Hopkins University Baltimore Maryland

Sponsors (3)

Lead Sponsor Collaborator
Johns Hopkins University Alzheimer's Association, National Institute on Aging (NIA)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in neuropsychiatric symptoms as assessed by Neuropsychiatric Inventory (NPI) score The total score (frequency x severity) of the Neuropsychiatric Inventory (NPI) scale will be used to measure neuropsychiatric and behavioral symptoms. The NPI is a proxy rating of person with dementia's severity, frequency, and distress across 12 types of neuropsychiatric behavior problems. Scores can range from 0-144, with higher score indicating greater neuropsychiatric behavioral burden. Baseline to 12 weeks
Primary Change in quality of life as assessed by the Quality of life in Alzheimer's Disease (QOL-AD) tool The total score (sum of all items) for the Quality of life in Alzheimer's Disease (QOL-AD) tool will assess quality of life in the context of Alzheimer's Disease. The QOL-AD has a self-rated and proxy-rated version for persons with dementia, and was specifically developed for use in dementia. Scores can range from 13-52, with higher scores indicating better quality of life. Baseline to 12 weeks
Primary Change in subjective caregiver burden as assessed by the Zarit Burden Inventory-Short Form The total score (sum of items) for the Zarit Burden Inventory-Short Form-12 items (ZBI) will assess subjective caregiver burden. The ZBI short form is a self-rated 12-item measure of caregiver subjective burden rating related to caregiving for persons with dementia. Scores can range from 0-48, with higher scores indicating greater perceived burden. Baseline to 12 weeks
Primary Change in depressive symptoms in caregivers as assessed by The Patient Health Questionnaire (PHQ) - 9 The total score (sum of items) for the The Patient Health Questionnaire (PHQ) - 9 will assess depressive symptoms severity. The PHQ-9 is a self-rated 9 item measure of caregiver depressive symptoms. Scores can range from 0-27, with higher scores indicating greater depressive symptoms. Baseline to 12 weeks
Primary Change in speed of processing as assessed by the Pattern Comparison test The total score for the Pattern Comparison test will be used to assess speed of processing changes. The Pattern Comparison test is a neuropsychological test to measure volunteer cognitive speed processing. Higher scores indicate greater speeds of processing. Baseline to 12 weeks
Primary Change in Gait speed The time (minutes) it takes subjects to rise from a chair, walk 4 meters, turnaround and sit back down will be used to assess gait speed. This walking speed test to measure volunteer gait disability. Lower time scores indicates better gait functioning. Baseline to 12 weeks
Primary Change in executive functioning as assessed by Trail Making Test B The score for the Trail Making Test B will be used to measure volunteer executive functioning. Lower time score indicates better executive functioning. Baseline to 12 weeks
Primary Change in activity engagement as assessed by the Community Healthy Activities Model Program for Seniors activity questionnaire The total score from the Community Healthy Activities Model Program for Seniors activity questionnaire will be used to quantify engagement in various forms of activities over the course of a week. Scores can range from 0-168, with higher scores indicating greater activity engagement. Baseline to 12 weeks
Secondary Change in outpatient health services use as assessed by the Resource Utilization in Dementia/Services Utilization and Resources Survey This is a proxy rated measure (Resource Utilization in Dementia/Services Utilization and Resources Survey; SURFS) of family caregiver outpatient medical services. Total scores are for each category and represent counts of service type encounters (range 0-90) for outpatient medical services, with higher counts indicating more service type utilization. Baseline to 12 weeks
Secondary Change in home and community-based long term services and supports use health services use as assessed by the Resource Utilization in Dementia/Services Utilization and Resources Survey Community based long term services and supports is summarized by count of service type category, ranging from 0-12, with higher counts indicating more service category utilization. Baseline to 12 weeks
Secondary Change in objective caregiver burden as assessed by time estimates in performing tasks Two individual items ask caregivers to estimate hours per day spent doing caregiving activities, and hours per day spent with the person with dementia in a typical week. Objective measure of caregiver burden. Higher time estimates in performing these tasks indicate greater objective burden. Baseline to 12 weeks
Secondary Change in stress as assessed by the Elders Life Stress Inventory The investigators will use a total score of the Elders Life Stress Inventory to measure stress ratings by volunteers. The total score ranges from 0-31 and indicates the total sum of 31 different types of stressful life events over the observation period related to several domains of the persons life. Higher counts of stressful events represent greater stress. Baseline to 12 weeks
Secondary Time to transition from home The investigators will record the time (days) from randomization to transition from home using survival analyses. These exploratory analyses will estimate risk of all-cause transition out of home for person with dementia Baseline to 12 weeks
Secondary Change in depressive symptoms in senior companion volunteers as assessed by The Patient Health Questionnaire (PHQ) - 9 The total score (sum of items) for the The Patient Health Questionnaire (PHQ) - 9 will assess depressive symptoms severity in senior companion volunteers. The PHQ-9 is a self-rated 9 item measure of caregiver depressive symptoms. Scores can range from 0-27, with higher scores indicating greater depressive symptoms. Baseline to 12 weeks
See also
  Status Clinical Trial Phase
Completed NCT04079803 - PTI-125 for Mild-to-moderate Alzheimer's Disease Patients Phase 2
Completed NCT04044495 - Sleep, Rhythms and Risk of Alzheimer's Disease N/A
Terminated NCT03052712 - Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies N/A
Recruiting NCT04520698 - Utilizing Palliative Leaders In Facilities to Transform Care for Alzheimer's Disease N/A
Active, not recruiting NCT04606420 - Can Lifestyle Changes Reverse Early-Stage Alzheimer's Disease N/A
Recruiting NCT05820919 - Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase N/A
Terminated NCT03672474 - REGEnLIFE RGn530 - Feasibility Pilot N/A
Completed NCT03430648 - Is Tau Protein Linked to Mobility Function?
Recruiting NCT05557409 - A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation Phase 3
Recruiting NCT04522739 - Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease Phase 4
Recruiting NCT05288842 - Tanycytes in Alzheimer's Disease and Frontotemporal Dementia
Recruiting NCT04949750 - Efficacy of Paper-based Cognitive Training in Vietnamese Patients With Early Alzheimer's Disease N/A
Completed NCT06194552 - A Multiple Dose Study of the Safety and Pharmacokinetics of NTRX-07 Phase 1
Completed NCT03239561 - Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants Early Phase 1
Completed NCT03184467 - Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer Patients Phase 2
Active, not recruiting NCT03676881 - Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
Terminated NCT03487380 - Taxonomic and Functional Composition of the Intestinal Microbiome: a Predictor of Rapid Cognitive Decline in Patients With Alzheimer's Disease N/A
Completed NCT05538455 - Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases N/A
Recruiting NCT05328115 - A Study on the Safety, Tolerability and Immunogenicity of ALZ-101 in Participants With Early Alzheimer's Disease Phase 1
Completed NCT05562583 - SAGE-LEAF: Reducing Burden in Alzheimer's Disease Caregivers Through Positive Emotion Regulation and Virtual Support N/A